Achaogen Inc. (AKAO)

5.92 +0.24 (+4.225%)

IEX Real-Time Price

August 17, 2018 EST.

NASDAQ Global Market : Healthcare

Prev Close 5.68

Price Open 5.62

Volume: 477,498

Avg Volume: 1.05M

Market Cap: 267.64M

P/E Ratio -1.48

52 Wk Range 5.11-19.74



AKAO Short Interest Statistics


Report Date
Float Share
Short Interest
Short Ratio
Short % to Float

2018-07-31
36.76M
12.67M
10.33
34.47%

2018-07-13
36.35M
14.56M
8.32
40.05%

2018-06-29
36.35M
14.83M
10.91
40.80%

2018-06-15
36.41M
14.97M
20.95
41.11%




AKAO Earning Report


Report Date
Fiscal Period
Announce Time
Estimated EPS(#)
Actual EPS
Surprise Dollar

2018-05-14
Q1 2018
N/A
-0.92 (6)
0.00
0.00

2018-03-13
Q4 2017
N/A
-0.79 (7)
-0.98
-0.19

2018-02-27
Q4 2017
AMC
-0.79 (7)
-0.98
-0.19

2017-11-08
Q3 2017
AMC
-0.72 (6)
-0.98
-0.19

News

Entasis Therapeutics files for $86.25M initial public offering (2018-08-17 18:15 SeekingAlpha)

Clinical-stage biopharmaceutical firm Entasis Therapeutics has filed for an initial public offering for up to $86.25M. More news on: Tetraphase Pharmaceuticals, Shionogi & Co. Ltd. ADR, GlaxoSmithKline, Healthcare stocks news, IPOs, Read more …

 


Statistics

Shares Outstanding: 45.21M

Top 15 Institution Percent: 81.30

Price To Sales: 35.91

Price To Book: 4.54

Revenue: 577000

Gross Profit: N/A

Cash: 199.40M

Debt: 24.87M

Return On Assets: -80.56

Return On Equity: -137.72

Profit Margin: N/A

Price History

Beta: 0.81

50-day Moving Avg: 8.55

200-day Moving Avg: 11.03

YTD Change: -47.14

5-day Change: 1.72

1-month Change: -17.78

3-month Change: -52.60

6-month Change: -44.93

1-year Change: -66.91

Revenue Per Share: 0.00

Revenue Per Employee: 2466.00



Dividend

Dividend Yield: -

EX-Dividend Date: -

Dividend Rate: -


Company Profile

Name: Achaogen Inc.

Exchange: NASDAQ Global Market

Industry: Biotechnology

Sector: Healthcare

Website: http://www.achaogen.com

Achaogen Inc is a biopharmaceutical company committed to the discovery, development, and commercialization of novel antibacterials to treat multi-drug resistant (MDR) gram-negative infections.